RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
REPLIGEN CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$176.43+1.01 (+0.58%)
Close on Oct 19, 2026
- Market cap
- $9.99B
- P/E (TTM)
- 205.2
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2010 to 2025
Gross margin
52.3%−4.9 pts over 5 years
Operating margin
7.5%−11.6 pts over 5 years
Net margin
6.6%−9.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +16.4% | -2.7% | +15.0% | +24.3% | |
| Gross profit | +40.6% | -5.4% | +13.0% | +23.1% | |
| Operating income | – | -37.4% | -4.6% | +14.9% | |
| Net income | – | -35.9% | -4.0% | +18.0% | |
| EPS, diluted | – | -35.7% | -5.0% | +11.9% | |
| Free cash flow | -37.3% | +2.5% | +18.5% | +22.4% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 8.0% | 4.6% | 2.4% | |
| Return on assets | 5.4% | 3.6% | 1.7% | |
| Current ratio | 8.74 | 2.83 | 8.37 | |
| Interest coverage | 4.2× | 6.5× | 2.6× | |
| Inventory turnover | 2.2× | 2.1× | 2.2× | |
| Capex to revenue | 4.1% | 6.1% | 3.2% | |
| Diluted shares | 0M | 0M | 0M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Repligen generated $697.83M from operations and spent $251.73M on capital expenditure, dividends and share buybacks. 94% of that went back into the business.
Generated
$697.83M
Used
$251.73M
Capital expenditure$237.34M94%Dividends$00%Share buybacks$14.39M6%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin6.6%
×Asset turnover0.26×
×Equity multiplier1.42×
=Return on equity, FY20252.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 6.6% | 0.26× | 1.42× | 2.4% |
| FY2024 | -4.0% | 0.22× | 1.44× | -1.3% |
| FY2023 | 5.6% | 0.24× | 1.38× | 1.8% |
| FY2022 | 23.2% | 0.33× | 1.34× | 10.2% |
| FY2021 | 19.1% | 0.31× | 1.30× | 7.8% |
| FY2020 | 16.4% | 0.22× | 1.28× | 4.6% |
| FY2019 | 7.9% | 0.25× | 1.30× | 2.6% |
| FY2018 | 8.6% | 0.26× | 1.26× | 2.8% |
| FY2017 | 20.1% | 0.27× | 1.36× | 7.5% |
| FY2016 | 11.2% | 0.48× | 1.49× | 8.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$48.89M
- Cash generatingOperating cash flow above zero$117.42M
- Return on assets improvedROA up on the prior year-0.9% → 1.7%
- Earnings backed by cashOperating cash flow above net income$117.42M vs $48.89M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose8.41 → 8.37
- No dilutionShare count did not rise0M → 0M
- Gross margin improvedGross margin up on the prior year43.29% → 52.32%
- More efficientAsset turnover rose0.22 → 0.26